アラスカ州における肺がんの臨床試験
アラスカ州内の拠点で、肺がんに関する7件の研究が参加者を募集しています。
アラスカ州内の都市
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Fairbanks Memorial Hospital, Fairbanks
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Anchorage Associates in Radiation Medicine, Anchorage
- Alaska Breast Care and Surgery LLC, Anchorage
- Alaska Oncology and Hematology LLC, Anchorage
- 他3件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Alaska Oncology and Hematology LLC, Anchorage
- Katmai Oncology Group, Anchorage
- Fairbanks Memorial Hospital, Fairbanks
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT04181060Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Alaska Oncology and Hematology, LLC, Anchorage
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Alaska Oncology and Hematology, Anchorage
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06793215Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Katmai Oncology Group, Anchorage
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Katmai Oncology Group, Anchorage
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/05/05更新 · NCT06616584ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。